JLK "JBS-01K Selected as Innovative Medical Device... Next Year to Be a Year of Sales Growth"

Kim Dong-min, CEO of JLK (Photo by JLK)

[Asia Economy Reporter Byeon Seon-jin] "Our product JBS-01K has been designated as an innovative medical device, and we expect next year to be a key point for expanding domestic sales."

Kim Dong-min, CEO of JLK, emphasized in an interview with Asia Economy on the 23rd, "An environment will be established where companies can challenge more innovative technologies." JBS-01K is a medical device that analyzes patients' magnetic resonance imaging (MRI) images and medical data using artificial intelligence (AI) to classify the causes of cerebral infarction. JBS-01K was the first medical device selected under the Ministry of Health and Welfare's 'Innovative Medical Device Integrated Review and Evaluation System' and will be available for non-reimbursed use in hospitals for 3 to 5 years starting from the end of January next year.

Until now, medical devices applying innovative technology had to go through complicated procedures such as approval from the Ministry of Food and Drug Safety and innovative medical technology evaluation by the Korea Health Industry Development Institute, which caused a long time before product commercialization. In particular, although JBS-01K was approved by the Ministry of Food and Drug Safety four years ago, commercialization was difficult because insurance reimbursement was not confirmed. With JBS-01K designated under the Ministry of Health and Welfare's Innovative Medical Device Integrated Review and Evaluation System, market entry will be faster, and medical benefits for patients requiring various treatments can be enhanced.

JLK plans to actively utilize its domestic hospital network for product commercialization. Secondary opinions on ambiguous lesions will be possible, and demand in emergency rooms is expected to be high. CEO Kim said, "Since cerebral infarction has a high possibility of recurrence, it is important to accurately identify the cause," adding, "JBS-01K enables personalized treatment by detecting small lesions, accurately classifying stroke types, and establishing preventive treatments."

JBS-01K secured supply channels by providing more than 35 solutions, including stroke solutions, to 14 large hospitals nationwide through the 'Medical AI Clinic' consortium government project in June. In October, it was selected for the 'Digital Healthcare Medical Device Demonstration Support Project' and supplied products to Keimyung University Dongsan Medical Center. CEO Kim emphasized, "We will continue to actively pursue global market expansion beyond Korea and show rapid growth domestically and internationally in the stroke field."

This content was produced with the assistance of AI translation services.